Our goal is to build Kinaset into a leading respiratory therapeutics company focused on patients starting with KN-002.
Robert Clarke - CEO Kinaset
Kinaset Therapeutics was founded in 2020 through a Series A round of 40 million USD by 5AM Ventures, Atlas venture and Gimv. Funds will be used to support the clinical development of KN-002, a novel dry powder inhalable pan-JAK inhibitor for the treatment of eosinophilic and non-eosinophilic severe asthma.
KN-002 comes with an exclusive global in-license and development agreement with Vectura Group plc (LSE:VEC) to develop and commercialize KN-002 (formerly known as VR588). A first clinical trial in healthy volunteers and patients are poised to begin in the first half of 2021.
When ambition meets ambition
Kinaset Therapeutics intends to develop novel therapeutics that can positively impact people affected by intractable diseases, including severe asthma. Asthma is a complex and heterogeneous disease affecting over 300 million people worldwide, with approximately 10% of patients having severe asthma who suffer from frequent exacerbations, compromised lung function, and a reduced quality of life.
We are excited to be part of Kinaset Therapeutics, and to support the company in bringing KN-002 to the clinic. Kinaset Therapeutics perfectly fits Gimv’s strategy of investing in drug development companies combining solid science, a strong data package and an experienced team.
Together, we build a leading company
The best-in-class profile and tailormade dry-powder formulation captured our interest from the early start. Together with this very experienced and dedicated management team we are convinced KN-002 can make a real difference to severe asthma patients that have limited treatment options today.